Abstract: A toner for electrostatic image development includes: toner particles; perovskite compound particles externally added to the toner particles; and silica particles (S) that are externally added to the toner particles and include an elemental nitrogen-containing compound containing elemental molybdenum and in which the ratio NMo/NSi of a Net intensity NMo of elemental molybdenum that is measured by X-ray fluorescence analysis to a Net intensity NSi of elemental silicon that is measured by the X-ray fluorescence analysis is from 0.035 to 0.45 inclusive.

Abstract: A noise generation cause identifying method and a noise generation cause identifying device are provided. A response correcting process corrects a sound signal obtained through a sound signal obtaining process based on obtained model information so that a frequency response of the obtained sound signal approaches a frequency response of a learning sound signal. A variable obtaining process obtains a variable output from a map by inputting the corrected sound signal to the map. A cause identifying process identifies a generation cause of a sound picked up by a microphone using the variable obtained through the variable obtaining process.

Abstract: A result confirmation unit (204) computes a state space probability that is a probability that a verification target device (300) has not correctly prepared a state space having a quantum state stored therein, a Pauli measurement probability that is a probability that the verification target device (300) has not correctly performed Pauli Z measurement and Pauli X measurement, and a magic state probability that is a probability that the verification target device (300) has not generated a magic state of CCZ. Then, using the state space probability, the Pauli measurement probability, and the magic state probability, the result confirmation unit (204) computes a degree of approximation between a quantum state and the magic state of CCZ at the verification target device (300) and measurement accuracies of the Pauli Z measurement and the Pauli X measurement on the quantum state at the verification target device (300).

Abstract: An object of the present invention is to provide an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which includes a pyrochlore-type CeO2—ZrO2-based complex oxide having an improved oxygen storage capacity (particularly, an improved oxygen storage capacity after being exposed to a high temperature environment), and, in order to achieve the above-mentioned object, the present invention provides an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which contains a pyrochlore-type CeO2—ZrO2-based complex oxide that contains Y and Mg and thus exhibits an excellent oxygen storage capacity (particularly, an excellent oxygen storage capacity after being exposed to a high temperature environment).

Abstract: An object of the present invention is to provide an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which includes a pyrochlore-type CeO2—ZrO2-based complex oxide having an improved oxygen storage capacity (particularly, an improved oxygen storage capacity after being exposed to a high temperature environment), and, in order to achieve the above-mentioned object, the present invention provides an exhaust gas purification catalyst composition and an exhaust gas purification catalyst, each of which contains a pyrochlore-type CeO2—ZrO2-based complex oxide that contains Y and Mg and thus exhibits an excellent oxygen storage capacity (particularly, an excellent oxygen storage capacity after being exposed to a high temperature environment).

Abstract: According to one embodiment, an electronic device includes a power-supply voltage input terminal, a first capacitor, and a second capacitor. The first capacitor has a fixed capacitance. The second capacitor has a variable capacitance. The first capacitor and the second capacitor are connected in parallel to the power-supply voltage input terminal.

Abstract: Provided herein are novel thermostable phycobiliproteins. These proteins may be stabilized by the introduction of disulfide bonds which stabilize the protein. Modified cells expressing these thermostable phycobiliproteins and methods of making them are also provided.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.

Abstract: According to one embodiment, an electronic device includes a power-supply voltage input terminal, a first capacitor, and a second capacitor. The first capacitor has a fixed capacitance. The second capacitor has a variable capacitance. The first capacitor and the second capacitor are connected in parallel to the power-supply voltage input terminal.

Abstract: A memory system includes a non-volatile memory having a plurality of memory chips, a plurality of switches provided for each of the memory chips for switching on and off supply of power to the corresponding memory chip, and a memory controller configured to control the switches and data access to the non-volatile memory. The memory controller is further configured to determine whether there is a first memory chip among the plurality of memory chips that has no data item stored therein with an elapsed time from a most recent access thereof that is less than a threshold value, and if so, turn off the supply of power to the first memory chip while maintaining the supply of power to the plurality of memory chips other than the first memory chip.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: Aspects of this invention, inter alia, relate to novel systems for targeting, editing or manipulating DNA in a cell, using novel synthetic RNA-guided nucleases (sRGNs). The sRGNs are derived from wildtype or parental small type II CRISPR Cas9 endonucleases.

Abstract: The present application provides materials and methods for controlling gene editing. The present application also provides materials and methods for controlling transcriptional expression of guide RNAs and/or post-transcriptional expression of Cas nuclease.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant CORD, both ex vivo and in vivo; materials and methods for editing a GUCY2D gene in a human cell; and materials and methods for editing a R838H, R838C, or R838S mutation in a GUCY2D gene in a human cell. The present application also provides one or more gRNAs or sgRNAs for editing a GUCY2D gene; one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a R838H, R838C, or R838S mutation in a GUCY2D gene. The present application provides a therapeutic for treating a patient with autosomal dominant CORD. The present application also provides a kit for treating a patient with autosomal dominant CORD. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene; one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: The present application provides materials and methods for treating a patient with autosomal dominant RP, both ex vivo and in vivo; materials and methods for editing a RHO gene in a human cell; and materials and methods for editing a P23H mutation in a RHO gene in a human cell. In addition, the present application provides one or more gRNAs or sgRNAs for editing a RHO gene; one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene; and a therapeutic comprising at least one or more gRNAs or sgRNAs for editing a P23H mutation in a RHO gene. The present application provides a therapeutic for treating a patient with autosomal dominant RP. The present application provides a kit for treating a patient with autosomal dominant RP. In addition, the present application provides a self-inactivating CRISPR-Cas system.

Abstract: Provided are compositions and methods for the treatment of hemoglobinopathies such as thalassemias and sickle cell disease. Compositions and methods include one or more endonuclease(s) or endonuclease fusion protein(s), including one or more homing endonuclease(s) and/or homing endonuclease fusion protein(s) and/or CRISPR endonuclease(s) and/or CRISPR endonuclease fusion protein(s): (a) to disrupt a Bcl11a coding region; (b) to disrupt a Bcl11a gene regulatory region; (c) to modify an adult human ?-globin locus; (d) to disrupt a HbF silencing DNA regulatory element or pathway, such as a Bcl11a-regulated HbF silencing region; (e) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; (f) to mutate one or more ?-globin gene promoter(s) to achieve increased expression of a ?-globin gene; and/or (g) to correct one or more ?-globin gene mutation(s).

Abstract: A memory system includes a non-volatile memory having a plurality of memory chips, a plurality of switches provided for each of the memory chips for switching on and off supply of power to the corresponding memory chip, and a memory controller configured to control the switches and data access to the non-volatile memory. The memory controller is further configured to determine whether there is a first memory chip among the plurality of memory chips that has no data item stored therein with an elapsed time from a most recent access thereof that is less than a threshold value, and if so, turn off the supply of power to the first memory chip while maintaining the supply of power to the plurality of memory chips other than the first memory chip.

Abstract: This disclosure describes techniques for creating stable, targeted mutations in Spirulina (Athrospiria) and Spirulina having stable, targeted mutations.